Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 2/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | MARK3 | P27448 | 2/20 | 0.68 |
| ▸ | FLT3 | P36888 | 2/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.68 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.68 |
| ▸ | STK16 | O75716 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | YES1 | P07947 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646306 | 0.93 | PLK4 (0.71) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL2612678 | 0.91 | BTK (0.76) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL13803579 | 0.90 | PLK4 (0.73) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL2125065 | 0.90 | BTK (0.72) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL2121951 | 0.89 | ABL1 (0.65) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL2122628 | 0.88 | PLK4 (0.70) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL648262 | 0.87 | CDK9 (0.67) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL13652148 | 0.87 | PLK4 (0.52) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL2123042 | 0.87 | PTK2 (0.68) | CDK9PLK4FGFR1MARK3FLT3 | |
| SCHEMBL646073 | 0.86 | PLK4 (0.70) | CDK9PLK4FGFR1MARK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120095233-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095233-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8119655-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119655-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100160633-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160633-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100120717-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120717-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20090312288-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312288-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095233-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CDK9 99/4885PLK4 308/4885FGFR1 588/4885 |
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CDK9 78/4885PLK4 261/4885FGFR1 615/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CDK9 99/4885PLK4 308/4885FGFR1 588/4885 |
| US-20090312288-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CDK9 99/4885PLK4 308/4885FGFR1 588/4885 |
| US-20100160633-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CDK9 99/4885PLK4 308/4885FGFR1 588/4885 |
| US-20100120717-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | CDK9 84/4885PLK4 318/4885FGFR1 496/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | CDK9 99/4885PLK4 308/4885FGFR1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.